Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kaken to Increase Its No. of MRs to 800
November 22, 2010
- Yakult Honsha: Elplat Drives Pharma Business
November 22, 2010
- Eribulin Approved by FDA: Eisai
November 22, 2010
- Combined Sales of 23 Listed JPMA Member Companies Up 1.4%
November 22, 2010
- Sato to Launch Switch OTC Steroidal Agent
November 22, 2010
- GRU Criticizes Korosho for Not Discussing Range of OTC-like Drugs to Be Excluded from Insurance Coverage
November 22, 2010
- Kyorin: Sales Up 2.2% Driven by Kipres
November 22, 2010
- Price Settlement Rate 49.8% as of Sept. 30: CEO Kumakura of MEDIPAL
November 22, 2010
- Need for Economic Assessment of Drugs Pointed Out at Chuikyo
November 22, 2010
- Nippon Shinyaku: Cialis Drives Sales
November 22, 2010
- Alfresa: Operating Profits More than Double
November 22, 2010
- Afinitor Approved for Brain Tumors: Novartis
November 22, 2010
- Zeria: Asacol Drives Sales, Profits
November 22, 2010
- Suzuken: Operating Loss Reported for the First Time
November 22, 2010
- Enroll Japanese Patients in Early-Stage Global Studies
November 22, 2010
- Fuso: Generics Make Up for Decreases in Sales
November 22, 2010
- Toho: Sales Up 9.1% Boosted by Addition of SAYWELL
November 22, 2010
- EFPIA Survey Shows “Over-Quality” of Clinical Trials in Japan
November 22, 2010
- Torii: New Products Drive Sales
November 22, 2010
- VITAL KSK: Sales Remain Virtually Flat
November 22, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…